1
|
Paccione N, Guarnizo-Herrero V, Ramalingam M, Larrarte E, Pedraz JL. Application of 3D printing on the design and development of pharmaceutical oral dosage forms. J Control Release 2024; 373:463-480. [PMID: 39029877 DOI: 10.1016/j.jconrel.2024.07.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2024] [Revised: 07/11/2024] [Accepted: 07/15/2024] [Indexed: 07/21/2024]
Abstract
3D printing technologies confer an unparalleled degree of control over the material distribution on the structures they produce, which has led them to become an extremely attractive research topic in pharmaceutical dosage form development, especially for the design of personalized treatments. With fine tuning in material selection and careful design, these technologies allow to tailor not only the amount of drug administered but the biopharmaceutical behaviour of the dosage forms as well. While fused deposition modelling (FDM) is still the most studied 3D printing technology in this area, others are gaining more relevance, which has led to many new and exciting dosage forms developed during 2022 and 2023. Considering that these technologies, in time, will join the current manufacturing methods and with the ever-increasing knowledge on this topic, our review aims to explore the advantages and limitations of 3D printing technologies employed in the design and development of pharmaceutical oral dosage forms, giving special focus to the most important aspects governing the resulting drug release profiles.
Collapse
Affiliation(s)
- Nicola Paccione
- TECNALIA, Basque Research and Technology Alliance (BRTA), Leonardo Da Vinci 11, 01510 Miñano, Spain; Joint Research Laboratory (JRL) on Advanced Pharma Development, A Joint Venture of TECNALIA and University of the Basque Country, Centro de investigación Lascaray ikergunea, 01006 Vitoria-Gasteiz, Spain; NanoBioCel Group, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/ EHU), 01006 Vitoria-Gasteiz, Spain
| | - Víctor Guarnizo-Herrero
- Department of Biomedical Sciences, Faculty of Pharmacy, University of Alcalá de Henares, Ctra Madrid-Barcelona Km 33, 600 28805 Madrid, Spain
| | - Murugan Ramalingam
- Joint Research Laboratory (JRL) on Advanced Pharma Development, A Joint Venture of TECNALIA and University of the Basque Country, Centro de investigación Lascaray ikergunea, 01006 Vitoria-Gasteiz, Spain; NanoBioCel Group, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/ EHU), 01006 Vitoria-Gasteiz, Spain; Bioaraba Health Research Institute, Jose Atxotegi, s/n, 01009 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain.; IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain; School of Basic Medical Sciences, Binzhou Medical University, Yantai 264003, People's Republic of China
| | - Eider Larrarte
- TECNALIA, Basque Research and Technology Alliance (BRTA), Leonardo Da Vinci 11, 01510 Miñano, Spain; Joint Research Laboratory (JRL) on Advanced Pharma Development, A Joint Venture of TECNALIA and University of the Basque Country, Centro de investigación Lascaray ikergunea, 01006 Vitoria-Gasteiz, Spain.
| | - José Luis Pedraz
- Joint Research Laboratory (JRL) on Advanced Pharma Development, A Joint Venture of TECNALIA and University of the Basque Country, Centro de investigación Lascaray ikergunea, 01006 Vitoria-Gasteiz, Spain; NanoBioCel Group, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/ EHU), 01006 Vitoria-Gasteiz, Spain; Bioaraba Health Research Institute, Jose Atxotegi, s/n, 01009 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain..
| |
Collapse
|
2
|
Barrientos BA, Real DA, Rossetti A, Ambrosioni FE, Allemandi DA, Palma SD, Real JP. 3D printed scaffolds as delivery devices for nanocrystals: A proof of concept loading Atorvastatin with enhanced properties for sublingual route of administration. Int J Pharm 2024; 661:124396. [PMID: 38944168 DOI: 10.1016/j.ijpharm.2024.124396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2024] [Revised: 06/25/2024] [Accepted: 06/26/2024] [Indexed: 07/01/2024]
Abstract
Increasing the solubility of drugs is a recurrent objective of pharmaceutical research, and one of the most widespread strategies today is the formulation of nanocrystals (NCs). Beyond the many advantages of formulating NCs, their incorporation into solid dosage forms remains a challenge that limits their use. In this work, we set out to load Atorvastatin NCs (ATV-NCs) in a delivery device by combining 3D scaffolds with an "in situ" loading method such as freeze-drying. When comparing two infill patterns for the scaffolds at two different percentages, the one with the highest NCs load was chosen (Gyroid 20 % infill pattern, 13.8 ± 0.5 mg). Colloidal stability studies of NCs suggest instability in acidic media, and therefore, the system is postulated for use as a sublingual device, potentially bypassing stomach and hepatic first-pass effects. An ad hoc dissolution device was developed to mimic the release of actives. The nanometric size and properties acquired in the process were maintained, mainly in the dissolution rate and speed, achieving 100 % dissolution of the content in 180 s. Based on these results, the proof of concept represents an innovative approach to converting NCs suspensions into solid dosage forms.
Collapse
Affiliation(s)
- Bruno Andrés Barrientos
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET, Argentina; Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, X5000XHUA Córdoba, Argentina
| | - Daniel Andrés Real
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET, Argentina; Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, X5000XHUA Córdoba, Argentina
| | - Alan Rossetti
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET, Argentina; Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, X5000XHUA Córdoba, Argentina
| | - Franco E Ambrosioni
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET, Argentina; Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, X5000XHUA Córdoba, Argentina
| | - Daniel Alberto Allemandi
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET, Argentina; Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, X5000XHUA Córdoba, Argentina
| | - Santiago Daniel Palma
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET, Argentina; Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, X5000XHUA Córdoba, Argentina.
| | - Juan Pablo Real
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET, Argentina; Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, X5000XHUA Córdoba, Argentina.
| |
Collapse
|
3
|
Poudel I, Mita N, Babu RJ. 3D printed dosage forms, where are we headed? Expert Opin Drug Deliv 2024:1-20. [PMID: 38993098 DOI: 10.1080/17425247.2024.2379943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2024] [Accepted: 07/10/2024] [Indexed: 07/13/2024]
Abstract
INTRODUCTION 3D Printing (3DP) is an innovative fabrication technology that has gained enormous popularity through its paradigm shifts in manufacturing in several disciplines, including healthcare. In this past decade, we have witnessed the impact of 3DP in drug product development. Almost 8 years after the first USFDA approval of the 3D printed tablet Levetiracetam (Spritam), the interest in 3DP for drug products is high. However, regulatory agencies have often questioned its large-scale industrial practicability, and 3DP drug approval/guidelines are yet to be streamlined. AREAS COVERED In this review, major technologies involved with the fabrication of drug products are introduced along with the prospects of upcoming technologies, including AI (Artificial Intelligence). We have touched upon regulatory updates and discussed the burning limitations, which require immediate focus, illuminating status, and future perspectives on the near future of 3DP in the pharmaceutical field. EXPERT OPINION 3DP offers significant advantages in rapid prototyping for drug products, which could be beneficial for personalizing patient-based pharmaceutical dispensing. It seems inevitable that the coming decades will be marked by exponential growth in personalization, and 3DP could be a paradigm-shifting asset for pharmaceutical professionals.
Collapse
Affiliation(s)
- Ishwor Poudel
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, USA
| | - Nur Mita
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, USA
- Faculty of Pharmacy, Mulawarman University, Samarinda, Kalimantan Timur, Indonesia
| | - R Jayachandra Babu
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, USA
| |
Collapse
|
4
|
Racaniello GF, Silvestri T, Pistone M, D'Amico V, Arduino I, Denora N, Lopedota AA. Innovative Pharmaceutical Techniques for Paediatric Dosage Forms: A Systematic Review on 3D Printing, Prilling/Vibration and Microfluidic Platform. J Pharm Sci 2024; 113:1726-1748. [PMID: 38582283 DOI: 10.1016/j.xphs.2024.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2023] [Revised: 04/01/2024] [Accepted: 04/01/2024] [Indexed: 04/08/2024]
Abstract
The production of paediatric pharmaceutical forms represents a unique challenge within the pharmaceutical industry. The primary goal of these formulations is to ensure therapeutic efficacy, safety, and tolerability in paediatric patients, who have specific physiological needs and characteristics. In recent years, there has been a significant increase in attention towards this area, driven by the need to improve drug administration to children and ensure optimal and specific treatments. Technological innovation has played a crucial role in meeting these requirements, opening new frontiers in the design and production of paediatric pharmaceutical forms. In particular, three emerging technologies have garnered considerable interest and attention within the scientific and industrial community: 3D printing, prilling/vibration, and microfluidics. These technologies offer advanced approaches for the design, production, and customization of paediatric pharmaceutical forms, allowing for more precise dosage modulation, improved solubility, and greater drug acceptability. In this review, we delve into these cutting-edge technologies and their impact on the production of paediatric pharmaceutical forms. We analyse their potential, associated challenges, and recent developments, providing a comprehensive overview of the opportunities that these innovative methodologies offer to the pharmaceutical sector. We examine different pharmaceutical forms generated using these techniques, evaluating their advantages and disadvantages.
Collapse
Affiliation(s)
| | - Teresa Silvestri
- Department of Pharmacy, University of Naples Federico II, D. Montesano St. 49, 80131 Naples, Italy
| | - Monica Pistone
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Via E. Orabona, 4, 70125, Bari, Italy
| | - Vita D'Amico
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Via E. Orabona, 4, 70125, Bari, Italy
| | - Ilaria Arduino
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Via E. Orabona, 4, 70125, Bari, Italy
| | - Nunzio Denora
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Via E. Orabona, 4, 70125, Bari, Italy.
| | - Angela Assunta Lopedota
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Via E. Orabona, 4, 70125, Bari, Italy
| |
Collapse
|
5
|
Kreft K, Fanous M, Möckel V. The potential of three-dimensional printing for pediatric oral solid dosage forms. ACTA PHARMACEUTICA (ZAGREB, CROATIA) 2024; 74:229-248. [PMID: 38815205 DOI: 10.2478/acph-2024-0012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 01/04/2024] [Indexed: 06/01/2024]
Abstract
Pediatric patients often require individualized dosing of medicine due to their unique pharmacokinetic and developmental characteristics. Current methods for tailoring the dose of pediatric medications, such as tablet splitting or compounding liquid formulations, have limitations in terms of dosing accuracy and palatability. This paper explores the potential of 3D printing as a solution to address the challenges and provide tailored doses of medication for each pediatric patient. The technological overview of 3D printing is discussed, highlighting various 3D printing technologies and their suitability for pharmaceutical applications. Several individualization options with the potential to improve adherence are discussed, such as individualized dosage, custom release kinetics, tablet shape, and palatability. To integrate the preparation of 3D printed medication at the point of care, a decentralized manufacturing model is proposed. In this setup, pharmaceutical companies would routinely provide materials and instructions for 3D printing, while specialized compounding centers or hospital pharmacies perform the printing of medication. In addition, clinical opportunities of 3D printing for dose-finding trials are emphasized. On the other hand, current challenges in adequate dosing, regulatory compliance, adherence to quality standards, and maintenance of intellectual property need to be addressed for 3D printing to close the gap in personalized oral medication.
Collapse
Affiliation(s)
- Klemen Kreft
- 1Lek Pharmaceuticals d.d., a Sandoz Company, 1000 Ljubljana, Slovenia
| | | | | |
Collapse
|
6
|
Rana D, Beladiya J, Sheth D, Salave S, Sharma A, Jindal AB, Patel R, Benival D. Precise Fabrication of Ocular Inserts Using an Innovative Laser-Driven CaliCut Technology: In Vitro and in Vivo Evaluation. J Pharm Sci 2024; 113:1339-1350. [PMID: 38123067 DOI: 10.1016/j.xphs.2023.12.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2023] [Revised: 12/14/2023] [Accepted: 12/14/2023] [Indexed: 12/23/2023]
Abstract
Ocular inserts offer distinct advantages, including a preservative-free drug delivery system, the ability to provide tailored drug release, and ease of administration. The present research paper delves into the development of an innovative ocular insert using CaliCut technology. Complementing the hot melt extrusion (HME) process, CaliCut, an advanced technology in ocular insert development, employs precision laser gauging to achieve impeccable cutting of inserts with desired dimensions. Its intelligent control over the stretching process through auto feedback-based belt speed adjustment ensures unparalleled accuracy and consistency in dosage form manufacturing. Dry eye disease (DED) poses a significant challenge to ocular health, necessitating innovative approaches to alleviate its symptoms. In this pursuit, castor oil has emerged as a promising therapeutic agent, offering beneficial effects by increasing the thickness of the lipid layer in the tear film, thus improving tear film stability, and reducing tear evaporation. To harness these advantages, this study focuses on the development and comprehensive characterization of castor oil-based ocular inserts. Additionally, in-vivo irritancy evaluation in rabbits has been undertaken to assess the inserts' safety and biocompatibility. By harnessing the HME and CaliCut techniques in the formulation process, the study demonstrates their instrumental role in facilitating the successful development of ocular inserts.
Collapse
Affiliation(s)
- Dhwani Rana
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research -Ahmedabad (NIPER-A), India
| | - Jayesh Beladiya
- Department of Pharmacology, L.M. College of Pharmacy, Ahmedabad, India
| | - Devang Sheth
- Department of Pharmacology, L.M. College of Pharmacy, Ahmedabad, India
| | - Sagar Salave
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research -Ahmedabad (NIPER-A), India
| | - Amit Sharma
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research -Ahmedabad (NIPER-A), India
| | - Anil B Jindal
- Department of Pharmacy, Birla Institute of Technology and Science Pilani (BITS PILANI), Pilani Campus, Rajasthan, 333031, India
| | - Rikin Patel
- Graduate School of Pharmacy, Gujarat Technological University Gandhinagar Campus, Gandhinagar, 382028, India
| | - Derajram Benival
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research -Ahmedabad (NIPER-A), India.
| |
Collapse
|
7
|
Lenhart J, Pöstges F, Wagner KG, Lunter DJ. Evaluation of Printability of PVA-Based Tablets from Powder and Assessment of Critical Rheological Parameters. Pharmaceutics 2024; 16:553. [PMID: 38675214 PMCID: PMC11054527 DOI: 10.3390/pharmaceutics16040553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Revised: 04/13/2024] [Accepted: 04/16/2024] [Indexed: 04/28/2024] Open
Abstract
Fused deposition modeling (FDM) is a rather new technology in the production of personalized dosage forms. The melting and printing of polymer-active pharmaceutical ingredient (API)-mixtures can be used to produce oral dosage forms with different dosage as well as release behavior. This process is utilized to increase the bioavailability of pharmaceutically relevant active ingredients that are poorly soluble in physiological medium by transforming them into solid amorphous dispersions (ASD). The release from such ASDs is expected to be faster and higher compared to the raw materials and thus enhance bioavailability. Printing directly from powder while forming ASDs from loperamide in Polyvinylalcohol was realized. Different techniques such as a change in infill and the incorporation of sorbitol as a plastisizer to change release patterns as well as a non-destructive way for the determination of API distribution were shown. By measuring the melt viscosities of the mixtures printed, a rheological model for the printer used is proposed.
Collapse
Affiliation(s)
- Jonas Lenhart
- Department of Pharmaceutical Technology, Eberhard Karls University, 72076 Tuebingen, Germany;
| | - Florian Pöstges
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany; (F.P.); (K.G.W.)
| | - Karl G. Wagner
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany; (F.P.); (K.G.W.)
| | - Dominique J. Lunter
- Department of Pharmaceutical Technology, Eberhard Karls University, 72076 Tuebingen, Germany;
| |
Collapse
|
8
|
Hess F, Kipping T, Weitschies W, Krause J. Understanding the Interaction of Thermal, Rheological, and Mechanical Parameters Critical for the Processability of Polyvinyl Alcohol-Based Systems during Hot Melt Extrusion. Pharmaceutics 2024; 16:472. [PMID: 38675133 PMCID: PMC11055164 DOI: 10.3390/pharmaceutics16040472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2024] [Revised: 03/18/2024] [Accepted: 03/26/2024] [Indexed: 04/28/2024] Open
Abstract
Hot melt extrusion (HME) is a common manufacturing process used in the pharmaceutical industry to improve the solubility of poorly soluble active pharmaceutical ingredients (API). The goal is to create an amorphous solid dispersion (ASD) where the amorphous form of the API is stabilized within a polymer matrix. Traditionally, the development of pharmaceutically approved polymers has focused on requirements such as thermal properties, solubility, drug-polymer interactions, and biocompatibility. The mechanical properties of the material have often been neglected in the design of new polymers. However, new downstream methods require more flexible polymers or suitable plasticizer polymer combinations. In this study, two grades of the polymer polyvinyl alcohol (PVA), which is already established for HME, are investigated in terms of their mechanical, rheological, and thermal properties. The mechanical properties of the extruded filaments were tested by the three-point bending test. The rheological behavior was analyzed by oscillating plate measurements. Thermal analysis was performed by differential scanning calorimetry (DSC). In addition, the solid and liquid plasticizers mannitol, sorbitol, triacetin, triethyl citrate, polyethylene glycol, and glycerol were evaluated for use with PVA and their impact on the polymer properties was elaborated. Finally, the effects of the plasticizers are compared to each other, and the correlations are analyzed statistically using principal component analysis (PCA). Thereby, a clear ranking of the plasticizer effects was established, and a deeper understanding of the polymer-plasticizer interactions was created.
Collapse
Affiliation(s)
- Florian Hess
- Merck Life Science KGaA, Frankfurter Straße 250, 64293 Darmstadt, Germany
- Department of Biopharmaceutic and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Straße 3, 17487 Greifswald, Germany
| | - Thomas Kipping
- Merck Life Science KGaA, Frankfurter Straße 250, 64293 Darmstadt, Germany
| | - Werner Weitschies
- Department of Biopharmaceutic and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Straße 3, 17487 Greifswald, Germany
| | - Julius Krause
- Department of Biopharmaceutic and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Straße 3, 17487 Greifswald, Germany
| |
Collapse
|
9
|
Tong H, Zhang J, Ma J, Zhang J. Perspectives on 3D printed personalized medicines for pediatrics. Int J Pharm 2024; 653:123867. [PMID: 38310991 DOI: 10.1016/j.ijpharm.2024.123867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2023] [Revised: 01/27/2024] [Accepted: 01/27/2024] [Indexed: 02/06/2024]
Abstract
In recent years, the rapid advancement of three-dimensional (3D) printing technology has yielded distinct benefits across various sectors, including pharmaceuticals. The pharmaceutical industry has particularly experienced advantages from the utilization of 3D-printed medications, which have invigorated the development of tailored drug formulations. The approval of 3D-printed drugs by the U.S. Food and Drug Administration (FDA) has significantly propelled personalized drug delivery. Additionally, 3D printing technology can accommodate the precise requirements of pediatric drug dosages and the complexities of multiple drug combinations. This review specifically concentrates on the application of 3D printing technology in pediatric preparations, encompassing a broad spectrum of uses and refined pediatric formulations. It compiles and evaluates the fundamental principles associated with the application of 3D printing technology in pediatric preparations, including its merits and demerits, and anticipates its future progression. The objective is to furnish theoretical underpinning for 3D printing technology to facilitate personalized drug delivery in pediatrics and to advocate for its implementation in clinical settings.
Collapse
Affiliation(s)
- Haixu Tong
- School of Pharmacy, and State Key Laboratory of Applied Organic Chemistry, Lanzhou 730000, China
| | - Juanhong Zhang
- School of Pharmacy, and State Key Laboratory of Applied Organic Chemistry, Lanzhou 730000, China; College of Life Science, Northwest Normal University, Lanzhou 730070, China
| | - Jing Ma
- School of Pharmacy, and State Key Laboratory of Applied Organic Chemistry, Lanzhou 730000, China
| | - Junmin Zhang
- School of Pharmacy, and State Key Laboratory of Applied Organic Chemistry, Lanzhou 730000, China.
| |
Collapse
|
10
|
Milliken RL, Quinten T, Andersen SK, Lamprou DA. Application of 3D printing in early phase development of pharmaceutical solid dosage forms. Int J Pharm 2024; 653:123902. [PMID: 38360287 DOI: 10.1016/j.ijpharm.2024.123902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 01/19/2024] [Accepted: 02/08/2024] [Indexed: 02/17/2024]
Abstract
Three-dimensional printing (3DP) is an emerging technology, offering the possibility for the development of dose-customized, effective, and safe solid oral dosage forms (SODFs). Although 3DP has great potential, it does come with certain limitations, and the traditional drug manufacturing platforms remain the industry standard. The consensus appears to be that 3DP technology is expected to benefit personalized medicine the most, but that it is unlikely to replace conventional manufacturing for mass production. The 3DP method, on the other hand, could prove well-suited for producing small batches as an adaptive manufacturing technique for enabling adaptive clinical trial design for early clinical studies. The purpose of this review is to discuss recent advancements in 3DP technologies for SODFs and to focus on the applications for SODFs in the early clinical development stages, including a discussion of current regulatory challenges and quality controls.
Collapse
Affiliation(s)
- Rachel L Milliken
- School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK
| | - Thomas Quinten
- Janssen Pharmaceutica, Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Sune K Andersen
- Janssen Pharmaceutica, Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Dimitrios A Lamprou
- School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.
| |
Collapse
|
11
|
Aguilar-de-Leyva Á, Casas M, Ferrero C, Linares V, Caraballo I. 3D Printing Direct Powder Extrusion in the Production of Drug Delivery Systems: State of the Art and Future Perspectives. Pharmaceutics 2024; 16:437. [PMID: 38675099 PMCID: PMC11054165 DOI: 10.3390/pharmaceutics16040437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2024] [Revised: 03/14/2024] [Accepted: 03/20/2024] [Indexed: 04/28/2024] Open
Abstract
The production of tailored, on-demand drug delivery systems has gained attention in pharmaceutical development over the last few years, thanks to the application of 3D printing technology in the pharmaceutical field. Recently, direct powder extrusion (DPE) has emerged among the extrusion-based additive manufacturing techniques. It is a one-step procedure that allows the direct processing of powdered formulations. The aim of this systematic literature review is to analyze the production of drug delivery systems using DPE. A total of 27 articles have been identified through scientific databases (Scopus, PubMed, and ScienceDirect). The main characteristics of the three types of 3D printers based on DPE have been discussed. The selection of polymers and auxiliary excipients, as well as the flowability of the powder mixture, the rheological properties of the molten material, and the printing temperatures have been identified as the main critical parameters for successful printing. A wide range of drug delivery systems with varied geometries and different drug release profiles intended for oral, buccal, parenteral, and transdermal routes have been produced. The ability of this technique to manufacture personalized, on-demand drug delivery systems has been proven. For all these reasons, its implementation in hospital settings in the near future seems promising.
Collapse
Affiliation(s)
| | - Marta Casas
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universidad de Sevilla, 41012 Sevilla, Spain; (Á.A.-d.-L.); (C.F.) (V.L.); (I.C.)
| | | | | | | |
Collapse
|
12
|
Conceição MDND, Anaya-Mancipe JM, Coelho AWF, Cardoso PHM, Thiré RMDSM. Application of starch-rich mango by-product as filler for the development of an additive manufacturing filament compound. Int J Biol Macromol 2024; 260:129519. [PMID: 38246441 DOI: 10.1016/j.ijbiomac.2024.129519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 12/22/2023] [Accepted: 01/13/2024] [Indexed: 01/23/2024]
Abstract
The surge in global polymeric waste underscores the imperative for biodegradable materials to substitute traditional polymers. Crucially, advancements are needed for emerging technologies like Materials Extrusion (ME) in additive manufacturing, where current biodegradable materials exhibit limitations. This work was based on the development of a biodegradable composite filament. The inner of the mango seed (kernel) and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) were used as raw materials. The properties of PHBV and mango by-product mixture were first evaluated by direct-extrusion printing. Then, the feasibility of manufacturing the filaments was studied. Initially, the kernel seed mango was characterized thermally, chemically, and morphologically by DSC, FTIR, and SEM, respectively. It was observed that the addition of mango by-product contributed to the decrease of PHBV crystallinity, resulting in the reduction of printed parts retraction and increases the Tg, as shown by the DMA. The structure of the native starch was preserved due to non-gelatinization, even after processing steps, as indicated by thermal, chemical, and morphological analyses. Finally, PHBV filaments containing mango by-products were fabricated, and prototypes were manufactured by ME to demonstrate the potential for market acceptance and commercialization of the studied filament.
Collapse
Affiliation(s)
- Marceli do Nascimento da Conceição
- Program of Metallurgical and Materials Engineering - PEMM/COPPE, Universidade Federal do Rio de Janeiro - UFRJ, Cidade Universitária, 21941-599 Rio de Janeiro, RJ, Brazil; Centro de Tecnologia Mineral - CETEM, Rio de Janeiro, RJ, Brazil.
| | - Javier Mauricio Anaya-Mancipe
- Program of Metallurgical and Materials Engineering - PEMM/COPPE, Universidade Federal do Rio de Janeiro - UFRJ, Cidade Universitária, 21941-599 Rio de Janeiro, RJ, Brazil.
| | - Arthur Wilson Fonseca Coelho
- Program of Metallurgical and Materials Engineering - PEMM/COPPE, Universidade Federal do Rio de Janeiro - UFRJ, Cidade Universitária, 21941-599 Rio de Janeiro, RJ, Brazil.
| | - Paulo Henrique Machado Cardoso
- Program of Metallurgical and Materials Engineering - PEMM/COPPE, Universidade Federal do Rio de Janeiro - UFRJ, Cidade Universitária, 21941-599 Rio de Janeiro, RJ, Brazil.
| | - Rossana Mara da Silva Moreira Thiré
- Program of Metallurgical and Materials Engineering - PEMM/COPPE, Universidade Federal do Rio de Janeiro - UFRJ, Cidade Universitária, 21941-599 Rio de Janeiro, RJ, Brazil.
| |
Collapse
|
13
|
Iqbal H, Fernandes Q, Idoudi S, Basineni R, Billa N. Status of Polymer Fused Deposition Modeling (FDM)-Based Three-Dimensional Printing (3DP) in the Pharmaceutical Industry. Polymers (Basel) 2024; 16:386. [PMID: 38337275 DOI: 10.3390/polym16030386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2023] [Revised: 01/22/2024] [Accepted: 01/29/2024] [Indexed: 02/12/2024] Open
Abstract
Additive manufacturing (AM) or 3D printing (3DP) is arguably a versatile and more efficient way for the production of solid dosage forms such as tablets. Of the various 3DP technologies currently available, fused deposition modeling (FDM) includes unique characteristics that offer a range of options in the production of various types of tablets. For example, amorphous solid dispersions (ASDs), enteric-coated tablets or poly pills can be produced using an appropriate drug/polymer combination during FDM 3DP. The technology offers the possibility of evolving personalized medicines into cost-effective production schemes at pharmacies and hospital dispensaries. In this review, we highlight key FDM features that may be exploited for the production of tablets and improvement of therapy, with emphasis on gastrointestinal delivery. We also highlight current constraints that must be surmounted to visualize the deployment of this technology in the pharmaceutical and healthcare industries.
Collapse
Affiliation(s)
- Heba Iqbal
- Pharmaceutical Sciences Department, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
| | - Queenie Fernandes
- College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
| | - Sourour Idoudi
- Pharmaceutical Sciences Department, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
| | - Renuka Basineni
- Pharmaceutical Sciences Department, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
| | - Nashiru Billa
- Pharmaceutical Sciences Department, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
| |
Collapse
|
14
|
Tripathi D, B H MP, Sahoo J, Kumari J. Navigating the Solution to Drug Formulation Problems at Research and Development Stages by Amorphous Solid Dispersion Technology. RECENT ADVANCES IN DRUG DELIVERY AND FORMULATION 2024; 18:79-99. [PMID: 38062659 DOI: 10.2174/0126673878271641231201065151] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Revised: 10/20/2023] [Accepted: 10/26/2023] [Indexed: 08/30/2024]
Abstract
Amorphous Solid Dispersions (ASDs) have indeed revolutionized the pharmaceutical industry, particularly in drug solubility enhancement. The amorphous state of a drug, which is a highenergy metastable state, can lead to an increase in the apparent solubility of the drug. This is due to the absence of a long-range molecular order, which results in higher molecular mobility and free volume, and consequently, higher solubility. The success of ASD preparation depends on the selection of appropriate excipients, particularly polymers that play a crucial role in drug solubility and physical stability. However, ASDs face challenges due to their thermodynamic instability or tendency to recrystallize. Measuring the crystallinity of the active pharmaceutical ingredient (API) and drug solubility is a complex process that requires a thorough understanding of drug-polymer miscibility and molecular interactions. Therefore, it is important to monitor drug solids closely during preparation, storage, and application. Techniques such as solid-state nuclear magnetic resonance (ssNMR), attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR), Raman spectroscopy, and dielectric spectroscopy have been successful in understanding the mechanism of drug crystallization. In addition, the continuous downstream processing of drug-loaded ASDs has introduced new automated methods for consistent ASD production. Advanced techniques such as hot melt extrusion, KinetiSol, electro spraying, and electrospinning have gained popularity. This review provides a comprehensive overview of Amorphous Solid Dispersions (ASDs) for oral drug delivery. It highlights the critical challenges faced during formulation, the impact of manufacturing variables, theoretical aspects of drug-polymer interaction, and factors related to drug-polymer miscibility. ASDs have been recognized as a promising strategy to improve the oral bioavailability of poorly water-soluble drugs. However, the successful development of an ASD-based drug product is not straightforward due to the complexity of the ASD systems. The formulation and process parameters can significantly influence the performance of the final product. Understanding the interactions between the drug and polymer in ASDs is crucial for predicting their stability and performance.
Collapse
Affiliation(s)
- Devika Tripathi
- Pranveer Singh Institute of Technology (Pharmacy), Uttar Pradesh, Kanpur, India
| | - Manjunatha Prabhu B H
- Department of Food Protection and Infestation Control, CSIR-CFTRI, Central Food Technological Research Institute, Mysore, India
| | - Jagannath Sahoo
- Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, NIMMS, Mumbai, India
| | - Jyoti Kumari
- Pranveer Singh Institute of Technology (Pharmacy), Uttar Pradesh, Kanpur, India
| |
Collapse
|
15
|
Roche A, Sanchez-Ballester NM, Bataille B, Delannoy V, Soulairol I. Fused Deposition Modelling 3D printing and solubility improvement of BCS II and IV active ingredients - A narrative review. J Control Release 2024; 365:507-520. [PMID: 38036003 DOI: 10.1016/j.jconrel.2023.11.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 11/10/2023] [Accepted: 11/21/2023] [Indexed: 12/02/2023]
Abstract
In the field of pharmaceutical research and development, Fused Deposition Modelling (FDM) 3D printing (3DP) has aroused growing interest within the last ten years. The use of thermoplastic polymers, combined with the melting process of the raw materials, offers the possibility of manufacturing amorphous solid dispersions (ASDs). In the pharmaceutical industry, the formulation of an ASD is a widely used strategy to improve the solubility of poorly soluble drugs (classified by the Biopharmaceutical Classification System (BCS) as class II and IV). In this review, an analysis of studies that have developed a FDM printed form containing a BCS class II or IV active substance was performed. The focus has been placed on the evaluation of the solid state of the active molecules (crystalline or amorphous) and on the study of their dissolution profile. Thus, the aim of this work is to highlight the interest of FDM 3DP to induce the amorphisation phenomenon of Class II and IV active substances by forming an ASD, and as result improving their solubility.
Collapse
Affiliation(s)
- Agnès Roche
- ICGM, Montpellier University, CNRS, ENSCM, Montpellier, France; Department of Pharmacy, Nîmes University Hospital, Nîmes, France
| | - Noelia M Sanchez-Ballester
- ICGM, Montpellier University, CNRS, ENSCM, Montpellier, France; Department of Pharmacy, Nîmes University Hospital, Nîmes, France.
| | - Bernard Bataille
- Department of Pharmacy, Nîmes University Hospital, Nîmes, France
| | - Violaine Delannoy
- ICGM, Montpellier University, CNRS, ENSCM, Montpellier, France; Department of Pharmacy, Nîmes University Hospital, Nîmes, France
| | - Ian Soulairol
- ICGM, Montpellier University, CNRS, ENSCM, Montpellier, France; Department of Pharmacy, Nîmes University Hospital, Nîmes, France.
| |
Collapse
|
16
|
Zhang B, Belton P, Teoh XY, Gleadall A, Bibb R, Qi S. An investigation into the effects of ink formulations of semi-solid extrusion 3D printing on the performance of printed solid dosage forms. J Mater Chem B 2023; 12:131-144. [PMID: 38050731 DOI: 10.1039/d3tb01868g] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/06/2023]
Abstract
Semi-solid extrusion (SSE) 3D printing has recently attracted increased attention for its pharmaceutical application as a potential method for small-batch manufacturing of personalised solid dosage forms. It has the advantage of allowing ambient temperature printing, which is especially beneficial for the 3D printing of thermosensitive drugs. In this study, the effects of polymeric compositions (single hydroxypropyl methylcellulose (HPMC) system and binary HPMC + polyvinylpyrrolidone (PVP) system), disintegrant (silicon oxide (SiO2)), and active pharmaceutical ingredients (tranexamic acid (TXA) and paracetamol (PAC)) on the printability of semisolid inks and the qualities of SSE printed drug-loaded tablets were investigated. Printability is defined by the suitability of the material for the process in terms of its physical properties during extrusions and post-extrusion, including rheology, solidification time, avoiding slumping, etc. The rheological properties of the inks were investigated as a function of polymeric compositions and drug concentrations and further correlated with the printability of the inks. The SSE 3D printed tablets were subjected to a series of physicochemical properties characterisations and in vitro drug release performance evaluations. The results indicated that an addition of SiO2 would improve 3D printing shape fidelity (e.g., pore area and porosity) by altering the ink rheology. The pores of HPMC + PVP + 5PAC prints completely disappeared after 12 hours of drying (pore area = 0 mm2). An addition of SiO2 significantly improved the pore area of the prints which are 3.5 ± 0.1 mm2. It was noted that the drug release profile of PAC significantly increased (p < 0.05) when additive SiO2 was incorporated in the formulation. This could be due to a significantly higher porosity of HPMC + PVP + SiO2 + PAC (70.3 ± 0.2%) compared to HPMC + PVP + PAC (47.6 ± 2.1%). It was also likely that SiO2 acted as a disintegrant speeding up the drug release process. Besides, the incorporation of APIs with different aqueous solubilities, as well as levels of interaction with the polymeric system showed significant impacts on the structural fidelity and subsequently the drug release performance of 3D printed tablets.
Collapse
Affiliation(s)
- Bin Zhang
- School of Pharmacy, University of East Anglia, Norwich, UK.
- Department of Mechanical and Aerospace Engineering, Brunel University London, London, UK.
| | - Peter Belton
- School of Chemistry, University of East Anglia, Norwich, UK
| | - Xin Yi Teoh
- School of Pharmacy, University of East Anglia, Norwich, UK.
- School of Pharmacy, University College London, London, UK
| | - Andrew Gleadall
- Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK
| | - Richard Bibb
- Nottingham School of Art & Design, Nottingham Trent University, UK
| | - Sheng Qi
- School of Pharmacy, University of East Anglia, Norwich, UK.
| |
Collapse
|
17
|
Dos Santos J, Kielholz T, Funk NL, Balbinot GDS, Daitx TDS, Petzhold CL, Buchner S, Collares FM, Windbergs M, Beck RCR. Poly(ɛ-caprolactone) and Eudragit E blends modulate the drug release profiles from FDM printlets. Int J Pharm 2023; 647:123533. [PMID: 37863446 DOI: 10.1016/j.ijpharm.2023.123533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Revised: 10/14/2023] [Accepted: 10/17/2023] [Indexed: 10/22/2023]
Abstract
Thermoplastic polymers have been used to produce filaments by hot melt extrusion (HME), which can be applied to obtain 3D printlets by fused deposition modelling (FDM). Poly(ε-caprolactone) (PCL) is a low melting point thermoplastic polymer that provides HME filaments with excellent mechanical and printability properties. However, due to the highly hydrophobic properties of PCL, they afford printlets with slow drug release behaviour. We hypothesized that blending a less hydrophobic polymer, the Eudragit E (EudE), with PCL could be an approach to increase the drug release rate from PCL 3D printlets. PCL and EudE were blended at different proportions, 50:50, 60:40, 70:30, and 80:20 (w/w), to produce HME filaments. They were produced with dexamethasone at 5 % (w/w) and were effectively extruded and printable by FDM, except that composed of 50:50 (w/w). Printlets had homogeneous distribution of their components. Their drug release behaviour was dependent on the ratio of the polymeric blends. The highest EudE ratio (60:40 w/w) afforded printlets showing the highest release rate. Therefore, adding up to 40 % (w/w) of EudE to PCL does not impair the mechanical and printability properties of its HME filaments. This innovative approach is proposed here to modulate the drug release behaviour from PCL printlets.
Collapse
Affiliation(s)
- Juliana Dos Santos
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia Universidade Federal do Rio Grande do Sul, Avenida Ipiranga, 2752, Porto Alegre, Rio Grande do Sul 90610-000, Brazil; Laboratório de Nanocarreadores e Impressão 3D em Tecnologia Farmacêutica (Nano3D), Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brasil
| | - Tobias Kielholz
- Institute of Pharmaceutical Technology and Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Max-von-Laue Straße 9, 60438 Frankfurt am Main, Germany
| | - Nadine Lysyk Funk
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia Universidade Federal do Rio Grande do Sul, Avenida Ipiranga, 2752, Porto Alegre, Rio Grande do Sul 90610-000, Brazil; Laboratório de Nanocarreadores e Impressão 3D em Tecnologia Farmacêutica (Nano3D), Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brasil
| | - Gabriela de Souza Balbinot
- Laboratório de Materiais Dentários, Faculdade de Odontologia, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2492/4(th) Floor, Porto Alegre, RS, Brazil
| | - Tales da Silva Daitx
- Instituto de Química, Universidade Federal do Rio Grande do Sul (UFRGS), Av. Bento Gonçalves - Agronomia, Porto Alegre, RS 90650-001, Brazil
| | - Cesar Liberato Petzhold
- Instituto de Química, Universidade Federal do Rio Grande do Sul (UFRGS), Av. Bento Gonçalves - Agronomia, Porto Alegre, RS 90650-001, Brazil
| | - Silvio Buchner
- Laboratório de Altas Pressões e Materiais Avançados (LAPMA), Instituto de Física, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
| | - Fabrício Mezzomo Collares
- Laboratório de Materiais Dentários, Faculdade de Odontologia, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2492/4(th) Floor, Porto Alegre, RS, Brazil
| | - Maike Windbergs
- Institute of Pharmaceutical Technology and Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Max-von-Laue Straße 9, 60438 Frankfurt am Main, Germany
| | - Ruy Carlos Ruver Beck
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia Universidade Federal do Rio Grande do Sul, Avenida Ipiranga, 2752, Porto Alegre, Rio Grande do Sul 90610-000, Brazil; Laboratório de Nanocarreadores e Impressão 3D em Tecnologia Farmacêutica (Nano3D), Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brasil.
| |
Collapse
|
18
|
Johannesson J, Wu M, Johansson M, Bergström CAS. Quality attributes for printable emulsion gels and 3D-printed tablets: Towards production of personalized dosage forms. Int J Pharm 2023; 646:123413. [PMID: 37726040 DOI: 10.1016/j.ijpharm.2023.123413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 09/10/2023] [Accepted: 09/11/2023] [Indexed: 09/21/2023]
Abstract
3D-printing technology offers a flexible manufacturing platform with the potential to address the need of personalized dosage forms. However, quality aspects of such small-scale, on-demand production of pharmaceutical products intended for personalization is still limited. The aim of this study was therefore to study critical quality control attributes of lipid tablets produced by semi-solid extrusion (SSE) 3D printing from emulsion gels incorporating a poorly water-soluble drug. Quality attributes for both the printable emulsion gel and the printed dosage forms were assessed. The emulsion gel was shown to be printable with accurate dosing for at least one month of storage at 4 °C. Tablets were 3D printed in different sizes and a correlation, R2 value of 0.99, was found between the weight and the drug content. The 3D-printed tablets complied with the mass and drug content uniformity requirements described in the European Pharmacopoeia.. Solid-state characterization of the tablets during short-term storage revealed no signs of crystallinity of the drug. Lastly, the lipid digestion and drug release were unchanged after short-term storage of the tablets. This study demonstrates the potential of SSE 3D printing for personalized dosing of a lipid-based formulation strategy and discusses central quality attributes for the printable formulation and the 3D-printed dosage form.
Collapse
Affiliation(s)
- Jenny Johannesson
- Department of Pharmacy, Uppsala University, SE 751 23 Uppsala, Sweden
| | - Mingjun Wu
- Department of Pharmacy, Uppsala University, SE 751 23 Uppsala, Sweden
| | - Mathias Johansson
- Department of Molecular Sciences, Swedish University of Agricultural Sciences (SLU), SE 750 07 Uppsala, Sweden
| | | |
Collapse
|
19
|
Jennotte O, Koch N, Lechanteur A, Rosoux F, Emmerechts C, Beeckman E, Evrard B. Feasibility study of the use of a homemade direct powder extrusion printer to manufacture printed tablets with an immediate release of a BCS II molecule. Int J Pharm 2023; 646:123506. [PMID: 37832701 DOI: 10.1016/j.ijpharm.2023.123506] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Revised: 10/09/2023] [Accepted: 10/10/2023] [Indexed: 10/15/2023]
Abstract
Among the various 3D printing techniques, FDM is the most studied in pharmaceutical research. However, it requires the fabrication of filaments with suitable mechanical properties using HME, which can be laborious and time-consuming. DPE has emerged as a single-step printing technique that can overcome FDM limits as it enables the direct printing of powder blends without the need of filaments. This study demonstrated the manufacturing of cylindrical-shaped printed tablets containing CBD, a BCS II molecule, with an immediate release. Different blends of PEO/E100 and PEO/SOL, each with 10 % of CBD, were printed and tested according to the Eur. Ph. for uncoated tablets. Each printed cylinder met the Eur. Ph. specifications for friability, mass variation and mass uniformity. However, only the E100-based formulations enabled a CBD immediate release, as formulations containing SOL formed a gel once in contact with the dissolution medium, reducing the drug dissolution rate.
Collapse
Affiliation(s)
- O Jennotte
- Laboratory of Pharmaceutical Technology and Biopharmacy, Department of Pharmacy, Center for Interdisciplinary Research on Medicines (CIRM), University of Liege, 4000 Liege, Belgium.
| | - N Koch
- Laboratory of Pharmaceutical Technology and Biopharmacy, Department of Pharmacy, Center for Interdisciplinary Research on Medicines (CIRM), University of Liege, 4000 Liege, Belgium
| | - A Lechanteur
- Laboratory of Pharmaceutical Technology and Biopharmacy, Department of Pharmacy, Center for Interdisciplinary Research on Medicines (CIRM), University of Liege, 4000 Liege, Belgium
| | - F Rosoux
- SIRRIS, Collective Centre of the Belgian Technology Industry, 4102 Liege Science Park, Belgium
| | - C Emmerechts
- SIRRIS, Collective Centre of the Belgian Technology Industry, 4102 Liege Science Park, Belgium
| | - E Beeckman
- SIRRIS, Collective Centre of the Belgian Technology Industry, 4102 Liege Science Park, Belgium
| | - Brigitte Evrard
- Laboratory of Pharmaceutical Technology and Biopharmacy, Department of Pharmacy, Center for Interdisciplinary Research on Medicines (CIRM), University of Liege, 4000 Liege, Belgium
| |
Collapse
|
20
|
Xue A, Li W, Tian W, Zheng M, Shen L, Hong Y. A Bibliometric Analysis of 3D Printing in Personalized Medicine Research from 2012 to 2022. Pharmaceuticals (Basel) 2023; 16:1521. [PMID: 38004387 PMCID: PMC10675621 DOI: 10.3390/ph16111521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 10/07/2023] [Accepted: 10/16/2023] [Indexed: 11/26/2023] Open
Abstract
In recent years, the 3D printing of personalized drug formulations has attracted the attention of medical practitioners and academics. However, there is a lack of data-based analyses on the hotspots and trends of research in this field. Therefore, in this study, we performed a bibliometric analysis to summarize the 3D printing research in the field of personalized drug formulation from 2012 to 2022. This study was based on the Web of Science Core Collection Database, and a total of 442 eligible publications were screened. Using VOSviewer and online websites for bibliometric analysis and scientific mapping, it was observed that annual publications have shown a significant growth trend over the last decade. The United Kingdom and the United States, which account for 45.5% of the total number of publications, are the main drivers of this field. The International Journal of Pharmaceutics and University College London are the most prolific and cited journals and institutions. The researchers with the most contributions are Basit, Abdul W. and Goyanes Alvaro. The keyword analysis concluded that the current research hotspots are "drug release" and "drug dosage forms". In conclusion, 3D printing has broad application prospects in the field of personalized drugs, which will bring the pharmaceutical industry into a new era of innovation.
Collapse
Affiliation(s)
- Aile Xue
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, No. 1200, Cai-Lun Road, Pudong District, Shanghai 201203, China; (A.X.); (W.L.); (W.T.); (M.Z.)
| | - Wenjie Li
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, No. 1200, Cai-Lun Road, Pudong District, Shanghai 201203, China; (A.X.); (W.L.); (W.T.); (M.Z.)
| | - Wenxiu Tian
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, No. 1200, Cai-Lun Road, Pudong District, Shanghai 201203, China; (A.X.); (W.L.); (W.T.); (M.Z.)
| | - Minyue Zheng
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, No. 1200, Cai-Lun Road, Pudong District, Shanghai 201203, China; (A.X.); (W.L.); (W.T.); (M.Z.)
| | - Lan Shen
- College of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, No. 1200, Cai-Lun Road, Pudong District, Shanghai 201203, China
| | - Yanlong Hong
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, No. 1200, Cai-Lun Road, Pudong District, Shanghai 201203, China; (A.X.); (W.L.); (W.T.); (M.Z.)
| |
Collapse
|
21
|
Muhindo D, Ashour EA, Almutairi M, Repka MA. Development of Subdermal Implants Using Direct Powder Extrusion 3D Printing and Hot-Melt Extrusion Technologies. AAPS PharmSciTech 2023; 24:215. [PMID: 37857937 DOI: 10.1208/s12249-023-02669-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Accepted: 10/03/2023] [Indexed: 10/21/2023] Open
Abstract
Implants are drug delivery platforms that consist of a drug-polymer matrix with the ability of providing a localized and efficient controlled release of the drug with minimal side effects and achievement of the desired therapeutic outcomes with low drug loadings. Direct powder extrusion (DPE) 3D printing technology involves the extrusion of material through a nozzle of the printer in the form of pellets or powder. The present study aimed at investigating the use of the CELLINK BIO X™ bioprinter using DPE 3D printing technique to fabricate and evaluate the impact of different shapes (cuboid, cylinder, and tube) of raloxifene hydrochloride (RFH)-loaded subdermal implants on the release of RFH from the implants. This study further evaluated the impact of different processing techniques, viz., hot-melt extrusion (HME) technology vs. DPE 3D printing technique, on the release of RFH from the implants fabricated by each processing technique. All the fabricated implants were characterized by XRD, DSC, SEM, and FTIR, and evaluated for their water uptake, mass loss, and in vitro RFH release. The current study successfully demonstrated a great opportunity of controlling and/or tuning the release of RFH from the subdermal implants by altering the implant shape, and hence surface area, and could be a great contribution and/or addition to the personalization of medicines and improvement of patient compliance.
Collapse
Affiliation(s)
- Derick Muhindo
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, Mississippi, 38677, USA
| | - Eman A Ashour
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, Mississippi, 38677, USA
| | - Mashan Almutairi
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, Mississippi, 38677, USA
- Department of Pharmaceutics, College of Pharmacy, University of Hail, 81442, Hail, Saudi Arabia
| | - Michael A Repka
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, Mississippi, 38677, USA.
- Pii Center for Pharmaceutical Technology, School of Pharmacy, University of Mississippi, University, Mississippi, 38677, USA.
| |
Collapse
|
22
|
Alogla A. Enhancing antioxidant delivery through 3D printing: a pathway to advanced therapeutic strategies. Front Bioeng Biotechnol 2023; 11:1256361. [PMID: 37860625 PMCID: PMC10583562 DOI: 10.3389/fbioe.2023.1256361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Accepted: 09/22/2023] [Indexed: 10/21/2023] Open
Abstract
The rapid advancement of 3D printing has transformed industries, including medicine and pharmaceuticals. Integrating antioxidants into 3D-printed structures offers promising therapeutic strategies for enhanced antioxidant delivery. This review explores the synergistic relationship between 3D printing and antioxidants, focusing on the design and fabrication of antioxidant-loaded constructs. Incorporating antioxidants into 3D-printed matrices enables controlled release and localized delivery, improving efficacy while minimizing side effects. Customization of physical and chemical properties allows tailoring of antioxidant release kinetics, distribution, and degradation profiles. Encapsulation techniques such as direct mixing, coating, and encapsulation are discussed. Material selection, printing parameters, and post-processing methods significantly influence antioxidant release kinetics and stability. Applications include wound healing, tissue regeneration, drug delivery, and personalized medicine. This comprehensive review aims to provide insights into 3D printing-assisted antioxidant delivery systems, facilitating advancements in medicine and improved patient outcomes for oxidative stress-related disorders.
Collapse
Affiliation(s)
- Ageel Alogla
- Industrial Engineering Department, College of Engineering (AlQunfudhah), Umm Al-Qura University, Mecca, Saudi Arabia
| |
Collapse
|
23
|
Rosch M, Gutowski T, Baehr M, Eggert J, Gottfried K, Gundler C, Nürnberg S, Langebrake C, Dadkhah A. Development of an immediate release excipient composition for 3D printing via direct powder extrusion in a hospital. Int J Pharm 2023; 643:123218. [PMID: 37467818 DOI: 10.1016/j.ijpharm.2023.123218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Revised: 07/07/2023] [Accepted: 07/08/2023] [Indexed: 07/21/2023]
Abstract
3D printing offers the possibility to prepare personalized tablets on demand, making it an intriguing technology for hospital pharmacies. For the implementation of 3D-printed tablets into the digital Closed Loop Medication Management system, the required tablet formulation and development of the manufacturing process as well as the pharmaceutical validation were conducted. The goal of the formulation development was to enable an optimal printing process and rapid dissolution of the printed tablets for the selected model drugs Levodopa/Carbidopa. The 3D printed tablets were prepared by direct powder extrusion. Printability, thermal properties, disintegration, dissolution, physical properties and storage stability were investigated by employing analytical methods such as HPLC-UV, DSC and TGA. The developed formulation shows a high dose accuracy and an immediate drug release for Levodopa. In addition, the tablets exhibit high crushing strength and very low friability. Unfortunately, Carbidopa did not tolerate the printing process. This is the first study to develop an immediate release excipient composition via direct powder extrusion in a hospital pharmacy setting. The developed process is suitable for the implementation in Closed-Loop Medication Management systems in hospital pharmacies and could therefore contribute to medication safety.
Collapse
Affiliation(s)
- Moritz Rosch
- Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Tobias Gutowski
- Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Michael Baehr
- Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Jan Eggert
- Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Karl Gottfried
- Institute for Applied Medical Informatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Christopher Gundler
- Institute for Applied Medical Informatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Sylvia Nürnberg
- Institute for Applied Medical Informatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Claudia Langebrake
- Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Adrin Dadkhah
- Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
| |
Collapse
|
24
|
Racaniello GF, Pistone M, Meazzini C, Lopedota A, Arduino I, Rizzi R, Lopalco A, Musazzi UM, Cilurzo F, Denora N. 3D printed mucoadhesive orodispersible films manufactured by direct powder extrusion for personalized clobetasol propionate based paediatric therapies. Int J Pharm 2023; 643:123214. [PMID: 37423374 DOI: 10.1016/j.ijpharm.2023.123214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 07/05/2023] [Accepted: 07/06/2023] [Indexed: 07/11/2023]
Abstract
The aim of this work is the development and production by Direct Powder Extrusion (DPE) 3D printing technique of novel oral mucoadhesive films delivering Clobetasol propionate (CBS), useful in paediatric treatment of Oral Lichen Planus (OLP), a rare chronic disease. The DPE 3D printing of these dosage forms can allow the reduction of frequency regimen, the therapy personalization, and reduction of oral cavity administration discomfort. To obtain suitable mucoadhesive films, different polymeric materials, namely hydroxypropylmethylcellulose or polyethylene oxide blended with chitosan (CS), were tested and hydroxypropyl-β-cyclodextrin was added to increase the CBS solubility. The formulations were tested in terms of mechanical, physico-chemical, and in vitro biopharmaceutical properties. The film showed a tenacious structure, with drug chemical-physical characteristics enhancement due to its partial amorphization during the printing stage and owing to cyclodextrins multicomponent complex formation. The presence of CS enhanced the mucoadhesive properties leading to a significant increase of drug exposure time on the mucosa. Finally, the printed films permeation and retention studies through porcine mucosae showed a marked retention of the drug inside the epithelium, avoiding drug systemic absorption. Therefore, DPE-printed films could represent a suitable technique for the preparation of mucoadhesive film potentially usable for paediatric therapy including OLP.
Collapse
Affiliation(s)
| | - Monica Pistone
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, Bari 70125, Italy
| | - Chiara Meazzini
- Department of Pharmaceutical Science, University of Milan, Via G. Colombo, 71, Milan 20133, Italy
| | - Angela Lopedota
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, Bari 70125, Italy
| | - Ilaria Arduino
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, Bari 70125, Italy
| | - Rosanna Rizzi
- Institute of Crystallography-CNR, Amendola St. 122/o, Bari 70126, Italy
| | - Antonio Lopalco
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, Bari 70125, Italy
| | - Umberto M Musazzi
- Department of Pharmaceutical Science, University of Milan, Via G. Colombo, 71, Milan 20133, Italy
| | - Francesco Cilurzo
- Department of Pharmaceutical Science, University of Milan, Via G. Colombo, 71, Milan 20133, Italy
| | - Nunzio Denora
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, Bari 70125, Italy.
| |
Collapse
|
25
|
Parulski C, Bya LA, Goebel J, Servais AC, Lechanteur A, Evrard B. Development of 3D printed mini-waffle shapes containing hydrocortisone for children's personalized medicine. Int J Pharm 2023:123131. [PMID: 37321464 DOI: 10.1016/j.ijpharm.2023.123131] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2023] [Revised: 06/06/2023] [Accepted: 06/08/2023] [Indexed: 06/17/2023]
Abstract
Hydrocortisone is mainly used in the substitution treatment of adrenal insufficiency which results in a dysregulation of cortisol. Compounding of hydrocortisone capsules remains the only low-dose oral treatment suitable for the pediatric population. However, capsules often show non-compliance in mass and content uniformity. Three-dimensional printing offers the prospect of practising personalized medicine for vulnerable patients like children. The goal of this work is to develop low-dose solid oral forms containing hydrocortisone by hot-melt extrusion coupled with fused deposition modeling for the pediatric population. Formulation, design and processes temperatures were optimized to produce printed forms with the desired characteristics. Red mini-waffle shapes containing drug loads of 2, 5 and 8 mg were successfully printed. This new 3D design allow to release more than 80% of the drug in 45 minutes indicating a conventional release like the one obtained with capsules. Mass and content uniformity, hardness and friability tests complied with European Pharmacopeia specifications, despite the considerable challenge of the small dimensions of the forms. This study demonstrates that FDM can be used to produce innovative pediatric-friendly printed shapes of an advanced pharmaceutical quality to practice personalize medicine.
Collapse
Affiliation(s)
- Chloé Parulski
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium.
| | - Laure-Anne Bya
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium
| | - Justine Goebel
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium
| | - Anne-Catherine Servais
- Laboratory for the Analysis of Medicines, Center for Interdisciplinary Research on Medicines (CIRM), Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium
| | - Anna Lechanteur
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium
| | - Brigitte Evrard
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium
| |
Collapse
|
26
|
Jørgensen AK, Ong JJ, Parhizkar M, Goyanes A, Basit AW. Advancing non-destructive analysis of 3D printed medicines. Trends Pharmacol Sci 2023; 44:379-393. [PMID: 37100732 DOI: 10.1016/j.tips.2023.03.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2023] [Revised: 03/22/2023] [Accepted: 03/22/2023] [Indexed: 04/28/2023]
Abstract
Pharmaceutical 3D printing (3DP) has attracted significant interest over the past decade for its ability to produce personalised medicines on demand. However, current quality control (QC) requirements for traditional large-scale pharmaceutical manufacturing are irreconcilable with the production offered by 3DP. The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) have recently published documents supporting the implementation of 3DP for point-of-care (PoC) manufacturing along with regulatory hurdles. The importance of process analytical technology (PAT) and non-destructive analytical tools in translating pharmaceutical 3DP has experienced a surge in recognition. This review seeks to highlight the most recent research on non-destructive pharmaceutical 3DP analysis, while also proposing plausible QC systems that complement the pharmaceutical 3DP workflow. In closing, outstanding challenges in integrating these analytical tools into pharmaceutical 3DP workflows are discussed.
Collapse
Affiliation(s)
- Anna Kirstine Jørgensen
- Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Jun Jie Ong
- Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Maryam Parhizkar
- Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Alvaro Goyanes
- Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain; FabRx Ltd., Henwood House, Henwood, Ashford TN24 8DH, UK; FabRx Artificial Intelligence, Carretera de Escairón 14, 27543 Currelos (O Saviñao) Lugo, Spain.
| | - Abdul W Basit
- Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK; FabRx Ltd., Henwood House, Henwood, Ashford TN24 8DH, UK; FabRx Artificial Intelligence, Carretera de Escairón 14, 27543 Currelos (O Saviñao) Lugo, Spain.
| |
Collapse
|
27
|
Elbadawi M, Basit A, Gaisford S. Energy Consumption and Carbon Footprint of 3D Printing in Pharmaceutical Manufacture. Int J Pharm 2023; 639:122926. [PMID: 37030639 DOI: 10.1016/j.ijpharm.2023.122926] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 03/30/2023] [Accepted: 04/01/2023] [Indexed: 04/10/2023]
Abstract
Achieving carbon neutrality is seen as an important goal in order to mitigate the effects of climate change, as carbon dioxide is a major greenhouse gas that contributes to global warming. Many countries, cities and organizations have set targets to become carbon neutral. The pharmaceutical sector is no exception, being a major contributor of carbon emissions (emitting approximately 55% more than the automotive sector for instance) and hence is in need of strategies to reduce its environmental impact. Three-dimensional (3D) printing is an advanced pharmaceutical fabrication technology that has the potential to replace traditional manufacturing tools. Being a new technology, the environmental impact of 3D printed medicines has not been investigated, which is a barrier to its uptake by the pharmaceutical industry. Here, the energy consumption (and carbon emission) of 3D printers is considered, focusing on technologies that have successfully been demonstrated to produce solid dosage forms. The energy consumption of 6 benchtop 3D printers was measured during standby mode and printing. On standby, energy consumption ranged from 0.03 to 0.17 kWh. The energy required for producing 10 printlets ranged from 0.06 to 3.08 kWh, with printers using high temperatures consuming more energy. Carbon emissions ranged between 11.60-112.16 g CO2 (eq) per 10 printlets, comparable with traditional tableting. Further analyses revealed that decreasing printing temperature was found to reduce the energy demand considerably, suggesting that developing formulations that are printable at lower temperatures can reduce CO2 emissions. The study delivers key initial insights into the environmental impact of a potentially transformative manufacturing technology and provides encouraging results in demonstrating that 3D printing can deliver quality medicines without being environmentally detrimental.
Collapse
Affiliation(s)
- Moe Elbadawi
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Abdul Basit
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Simon Gaisford
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
| |
Collapse
|
28
|
Maurizii G, Moroni S, Khorshid S, Aluigi A, Tiboni M, Casettari L. 3D-printed EVA-based patches manufactured by direct powder extrusion for personalized transdermal therapies. Int J Pharm 2023; 635:122720. [PMID: 36781085 DOI: 10.1016/j.ijpharm.2023.122720] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Revised: 02/08/2023] [Accepted: 02/09/2023] [Indexed: 02/13/2023]
Abstract
In recent years, 3D printing has attracted great interest in the pharmaceutical field as a promising tool for the on-demand manufacturing of patient-centered pharmaceutical forms. Among the existing 3D printing techniques, direct powder extrusion (DPE) resulted as the most practical approach thanks to the possibility to directly process excipients and drugs in a single step. The main goal of this work was to determine whether different grades of ethylene vinyl acetate (EVA) copolymer might be employed as new feedstock materials for the DPE technique to manufacture transdermal patches. By selecting two model drugs with different thermal behavior, (i.e., ibuprofen and diclofenac sodium) we also wanted to pay attention to the versatility of EVA excipient in preparing patches for customized transdermal therapies. EVA was combined with 30 % (w/w) of each model drugs. The physicochemical composition of the printed devices was investigated through Fourier-transform infrared spectroscopy, differential scanning calorimetry, and thermogravimetric analyses. FT-IR spectra confirmed that the starting materials were effectively incorporated into the final formulation, and thermal analyses demonstrated that the extrusion process altered the crystalline morphology of the raw polymers inducing the formation of crystals at lower thicknesses. Lastly, the drug release and permeation profile of the printed systems was evaluated for 48 h and showed to be dependent on the VA content of the EVA grade (74.5 % of ibuprofen released from EVA 4030AC matrix and 12.6 % of diclofenac sodium released from EVA1821A matrix). Hence, this study demonstrated that EVA and direct powder extrusion technique could be promising tools for manufacturing transdermal patches. By selecting the EVA grade with the appropriate VA content, drugs with dissimilar melting points could be printed preserving their thermal stability. Moreover, the desired drug release and permeation profile of the drug can be achieved, representing an important advantage in terms of personalized medicine.
Collapse
Affiliation(s)
- Giorgia Maurizii
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento, 6, 61029 Urbino, PU, Italy
| | - Sofia Moroni
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento, 6, 61029 Urbino, PU, Italy
| | - Shiva Khorshid
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento, 6, 61029 Urbino, PU, Italy
| | - Annalisa Aluigi
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento, 6, 61029 Urbino, PU, Italy
| | - Mattia Tiboni
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento, 6, 61029 Urbino, PU, Italy.
| | - Luca Casettari
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento, 6, 61029 Urbino, PU, Italy; Prosopika Srl, Via del Trabocchetto, 1, 61034, Fossombrone, PU, Italy
| |
Collapse
|
29
|
Gottschalk N, Bogdahn M, Quodbach J. 3D printing of amorphous solid dispersions: A comparison of fused deposition modeling and drop-on-powder printing. Int J Pharm X 2023; 5:100179. [PMID: 37025187 PMCID: PMC10070627 DOI: 10.1016/j.ijpx.2023.100179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 03/16/2023] [Accepted: 03/17/2023] [Indexed: 03/22/2023] Open
Abstract
Nowadays, a high number of pipeline drugs are poorly soluble and require solubility enhancement by e.g., manufacturing of amorphous solid dispersion. Pharmaceutical 3D printing has great potential in producing amorphous solid oral dosage forms. However, 3D printing techniques differ greatly in terms of processing as well as tablet properties. In this study, an amorphous formulation, which had been printed via Fused Deposition Modeling and drop-on-powder printing, also known as binder jetting, was characterized in terms of solid-state properties and physical stability. Solid state assessment was performed by differential scanning calorimetry, powder X-ray diffraction and polarized microscopy. The supersaturation performance of the amorphous solid dispersion was assessed via non-sink dissolution. We further evaluated both 3D printing techniques regarding their processability as well as tablet uniformity in terms of dimension, mass and content. Challenges and limitations of each 3D printing technique were discussed. Both techniques are feasible for the production of amorphous formulations. Results indicated that Fused Deposition Modeling is better suited for production, as the recrystallization tendency was lower. Still, filament production and printing presented a major challenge. Drop-on-powder printing can be a viable alternative for the production of amorphous tablets, when a formulation is not printable by Fused Deposition Modeling.
Collapse
|
30
|
McDonagh T, Belton P, Qi S. Manipulating drug release from 3D printed dual-drug loaded polypills using challenging polymer compositions. Int J Pharm 2023; 637:122895. [PMID: 36972779 DOI: 10.1016/j.ijpharm.2023.122895] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Revised: 03/17/2023] [Accepted: 03/24/2023] [Indexed: 03/28/2023]
Abstract
Combining multiple medications in a single dosage form has emerged as an important strategy for treating complex diseases and could help tackle the growing issue of polypharmacy. In this study we investigated the suitability of different dual-drug designs for achieving simultaneous, delayed and pulsatile drug release regimes using two model formulations: an immediate release erodible system of Eudragit E PO loaded with paracetamol; and an erodible swellable system of Soluplus loaded with felodipine. Both binary formulations, despite not fused deposition modelling (FDM) printable, were successfully printed using thermal droplet-based 3D printing method, Arburg Plastic Freeforming (APF), and exhibited good reproducibility. X-ray powder diffraction (XRPD), Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR-FTIR) and Differential Scanning Calorimetry (DSC) were used to assess drug-excipient interaction. The printed tablets were evaluated for drug release using in vitro dissolution testing. We found the simultaneous and delayed release designs were effective at generating the intended drug release profiles, giving insight into the types of dual-drug designs which can be used to create complex release profiles. In contrast the pulsatile tablet release was non-defined, highlighting the design limitations when using erodible materials.
Collapse
Affiliation(s)
| | - Peter Belton
- School of Chemistry, University of East Anglia, Norwich, UK
| | - Sheng Qi
- School of Pharmacy, University of East Anglia, Norwich, UK.
| |
Collapse
|
31
|
Muhindo D, Elkanayati R, Srinivasan P, Repka MA, Ashour EA. Recent Advances in the Applications of Additive Manufacturing (3D Printing) in Drug Delivery: A Comprehensive Review. AAPS PharmSciTech 2023; 24:57. [PMID: 36759435 DOI: 10.1208/s12249-023-02524-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Accepted: 01/26/2023] [Indexed: 02/11/2023] Open
Abstract
There has been a tremendous increase in the investigations of three-dimensional (3D) printing for biomedical and pharmaceutical applications, and drug delivery in particular, ever since the US FDA approved the first 3D printed medicine, SPRITAM® (levetiracetam) in 2015. Three-dimensional printing, also known as additive manufacturing, involves various manufacturing techniques like fused-deposition modeling, 3D inkjet, stereolithography, direct powder extrusion, and selective laser sintering, among other 3D printing techniques, which are based on the digitally controlled layer-by-layer deposition of materials to form various geometries of printlets. In contrast to conventional manufacturing methods, 3D printing technologies provide the unique and important opportunity for the fabrication of personalized dosage forms, which is an important aspect in addressing diverse patient medical needs. There is however the need to speed up the use of 3D printing in the biopharmaceutical industry and clinical settings, and this can be made possible through the integration of modern technologies like artificial intelligence, machine learning, and Internet of Things, into additive manufacturing. This will lead to less human involvement and expertise, independent, streamlined, and intelligent production of personalized medicines. Four-dimensional (4D) printing is another important additive manufacturing technique similar to 3D printing, but adds a 4th dimension defined as time, to the printing. This paper aims to give a detailed review of the applications and principles of operation of various 3D printing technologies in drug delivery, and the materials used in 3D printing, and highlight the challenges and opportunities of additive manufacturing, while introducing the concept of 4D printing and its pharmaceutical applications.
Collapse
Affiliation(s)
- Derick Muhindo
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA
| | - Rasha Elkanayati
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA
| | - Priyanka Srinivasan
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA
| | - Michael A Repka
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.,Pii Center for Pharmaceutical Technology, School of Pharmacy, University of Mississippi, University, MS, 38677, USA
| | - Eman A Ashour
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.
| |
Collapse
|
32
|
Nanocellulose-Based Biomaterial Ink Hydrogel for Uptake/Release of Bovine Serum Albumin. Polymers (Basel) 2023; 15:polym15040837. [PMID: 36850120 PMCID: PMC9967970 DOI: 10.3390/polym15040837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2023] [Revised: 02/03/2023] [Accepted: 02/07/2023] [Indexed: 02/10/2023] Open
Abstract
This study explores the potential of using nanocellulose extracted from oil palm empty fruit bunch (OPEFB) as a biomaterial ink for 3D printing. The research focuses on using nanocellulose hydrogels for the controlled uptake and release of proteins, with the specific protein solution being Bovine Serum Albumin (BSA). To provide a suitable material for the bioprinting process, the study examines the characteristics and properties of the printed hydrogels through various analyses, such as morphology, functional group, crystallinity, and compression test. Several parameters, such as initial concentration, temperature, and the presence of calcium chloride as an additional crosslinker, affect the protein uptake and release capabilities of the hydrogel. The study is important for biomedicine as it explores the behavior of protein uptake and release using nanocellulose and 3D printing and can serve as a preliminary study for using hydrogels in biological materials or living cells.
Collapse
|
33
|
Pistone M, Racaniello GF, Rizzi R, Iacobazzi RM, Arduino I, Lopalco A, Lopedota AA, Denora N. Direct cyclodextrin based powder extrusion 3D printing of budesonide loaded mini-tablets for the treatment of eosinophilic colitis in paediatric patients. Int J Pharm 2023; 632:122592. [PMID: 36626971 DOI: 10.1016/j.ijpharm.2023.122592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Revised: 01/04/2023] [Accepted: 01/05/2023] [Indexed: 01/08/2023]
Abstract
The purpose of this study was to combine direct powder extrusion (DPE) 3D printing and fluid bed coating techniques to create a budesonide (BD) loaded solid oral formulations for the treatment of eosinophilic colitis (EC) in paediatric patients. The preferred medication for EC treatment is BD, which has drawbacks due to its poor water solubility and low absorption. Additionally, since commercially available medications for EC treatment are created and approved for adult patients, administering them to children sometimes requires an off-label use and an impromptu handling, which can result in therapeutic ineffectiveness. The DPE 3D approach was investigated to create Mini-Tablets (MTs) to suit the swallowing, palatability, and dose flexibility control requirements needed by paediatric patients. Additionally, DPE 3D and the inclusion of hydroxypropyl-β-cyclodextrin in the initial powder mixture allowed for an improvement in the solubility and rate of BD dissolution in aqueous medium. Then, to accomplish a site-specific drug release at the intestinal level, MTs were coated with a layer of Eudragit FS 30D, an enteric polymer responsive at pH > 7.0 values. In vitro release experiments showed that film-coated MTs were suitable in terms of size and dose, enabling potential therapeutic customization and targeted delivery of BD to the colon.
Collapse
Affiliation(s)
- Monica Pistone
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, 70125 Bari, Italy
| | | | - Rosanna Rizzi
- Institute of Crystallography-CNR, Amendola St. 122/o, 70126 Bari, Italy
| | - Rosa Maria Iacobazzi
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, 70125 Bari, Italy
| | - Ilaria Arduino
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, 70125 Bari, Italy
| | - Antonio Lopalco
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, 70125 Bari, Italy
| | - Angela Assunta Lopedota
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, 70125 Bari, Italy.
| | - Nunzio Denora
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, 70125 Bari, Italy.
| |
Collapse
|
34
|
Serrano DR, Kara A, Yuste I, Luciano FC, Ongoren B, Anaya BJ, Molina G, Diez L, Ramirez BI, Ramirez IO, Sánchez-Guirales SA, Fernández-García R, Bautista L, Ruiz HK, Lalatsa A. 3D Printing Technologies in Personalized Medicine, Nanomedicines, and Biopharmaceuticals. Pharmaceutics 2023; 15:313. [PMID: 36839636 PMCID: PMC9967161 DOI: 10.3390/pharmaceutics15020313] [Citation(s) in RCA: 26] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Revised: 01/07/2023] [Accepted: 01/12/2023] [Indexed: 01/19/2023] Open
Abstract
3D printing technologies enable medicine customization adapted to patients' needs. There are several 3D printing techniques available, but majority of dosage forms and medical devices are printed using nozzle-based extrusion, laser-writing systems, and powder binder jetting. 3D printing has been demonstrated for a broad range of applications in development and targeting solid, semi-solid, and locally applied or implanted medicines. 3D-printed solid dosage forms allow the combination of one or more drugs within the same solid dosage form to improve patient compliance, facilitate deglutition, tailor the release profile, or fabricate new medicines for which no dosage form is available. Sustained-release 3D-printed implants, stents, and medical devices have been used mainly for joint replacement therapies, medical prostheses, and cardiovascular applications. Locally applied medicines, such as wound dressing, microneedles, and medicated contact lenses, have also been manufactured using 3D printing techniques. The challenge is to select the 3D printing technique most suitable for each application and the type of pharmaceutical ink that should be developed that possesses the required physicochemical and biological performance. The integration of biopharmaceuticals and nanotechnology-based drugs along with 3D printing ("nanoprinting") brings printed personalized nanomedicines within the most innovative perspectives for the coming years. Continuous manufacturing through the use of 3D-printed microfluidic chips facilitates their translation into clinical practice.
Collapse
Affiliation(s)
- Dolores R. Serrano
- Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
- Instituto Universitario de Farmacia Industrial, Universidad Complutense de Madrid, 28040 Madrid, Spain
| | - Aytug Kara
- Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
| | - Iván Yuste
- Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
| | - Francis C. Luciano
- Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
| | - Baris Ongoren
- Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
| | - Brayan J. Anaya
- Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
| | - Gracia Molina
- Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
| | - Laura Diez
- Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
| | - Bianca I. Ramirez
- Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
| | - Irving O. Ramirez
- Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
| | - Sergio A. Sánchez-Guirales
- Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
| | - Raquel Fernández-García
- Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
| | - Liliana Bautista
- Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
| | - Helga K. Ruiz
- Department of Physical Chemistry, Complutense University of Madrid, 28040 Madrid, Spain
| | - Aikaterini Lalatsa
- Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK
- CRUK Formulation Unit, School of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK
| |
Collapse
|
35
|
Algellay M, Roberts M, Bosworth L, Sarker SD, Fatokun AA, Ehtezazi T. The Use of Micro-Ribbons and Micro-Fibres in the Formulation of 3D Printed Fast Dissolving Oral Films. Pharmaceuticals (Basel) 2023; 16:ph16010079. [PMID: 36678576 PMCID: PMC9862838 DOI: 10.3390/ph16010079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2022] [Revised: 12/16/2022] [Accepted: 12/20/2022] [Indexed: 01/09/2023] Open
Abstract
Three-dimensional printing (3DP) allows production of novel fast dissolving oral films (FDFs). However, mechanical properties of the films may not be desirable when certain excipients are used. This work investigated whether adding chitosan micro-ribbons or cellulose microfibres will achieve desired FDFs by fused deposition modelling 3DP. Filaments containing polyvinyl alcohol (PVA) and paracetamol as model drug were manufactured at 170 °C. At 130 °C, filaments containing polyvinylpyrrolidone (PVP) and paracetamol were also created. FDFs were printed with plain or mesh patterns at temperatures of 200 °C (PVA) or 180 °C (PVP). Both chitosan micro-ribbons and cellulose micro-fibres improved filament mechanical properties at 1% w/w concentration in terms of flexibility and stiffness. The filaments were not suitable for printing at higher concentrations of chitosan micro-ribbons and cellulose micro-fibres. Furthermore, mesh FDFs containing only 1% chitosan micro-ribbons disintegrated in distilled water within 40.33 ± 4.64 s, while mesh FDFs containing only 7% croscarmellose disintegrated in 55.33 ± 2.86 s, and croscarmellose containing films showed signs of excipient scorching for PVA polymer. Cellulose micro-fibres delayed disintegration of PVA mesh films to 108.66 ± 3.68 s at 1% w/w. In conclusion, only chitosan micro-ribbons created a network of hydrophilic channels within the films, which allowed faster disintegration time at considerably lower concentrations.
Collapse
Affiliation(s)
- Marwan Algellay
- Centre for Natural Products Discovery, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK
| | - Matthew Roberts
- Centre for Natural Products Discovery, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK
| | - Lucy Bosworth
- Department of Eye and Vision Science, Institute of Life Course and Medical Sciences, University of Liverpool, 6 West Derby Street, Liverpool L7 8TX, UK
| | - Satyajit D. Sarker
- Centre for Natural Products Discovery, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK
| | - Amos A. Fatokun
- Centre for Natural Products Discovery, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK
| | - Touraj Ehtezazi
- Centre for Natural Products Discovery, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK
- Correspondence:
| |
Collapse
|
36
|
Burgos GL, Hernández-Espinell JR, Graciani-Massa T, Yao X, Borchardt-Setter KA, Yu L, López-Mejías V, Stelzer T. Role of Heteronucleants in Melt Crystallization of Crystalline Solid Dispersions. CRYSTAL GROWTH & DESIGN 2023; 23:49-58. [PMID: 38107196 PMCID: PMC10722868 DOI: 10.1021/acs.cgd.2c00444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2023]
Abstract
Few publications exist concerning polymorphic control during melt crystallization, particularly when employing heteronucleants. Here, the influence of a polymeric thin film (polyethylene terephthalate, PET) on the crystallization from melt of the polymorphic compound acetaminophen (ACM) in polyethylene glycol (PEG) was investigated. Molten ACM-PEG at different compositions was monitored using in situ Raman spectroscopy for nucleation induction time measurements and phase identification. Furthermore, X-ray diffraction (XRD) served to analyze the preferred orientation (PO) of the pastilles (solidified melt droplets) on PET-coated and uncoated substrates. The results indicate that PET-coated substrates qualitatively accelerate the nucleation of ACM form II (ACM II) in PEG compared to uncoated glass substrates. Additionally, the occurrence of ACM II in PEG was increased by an average of 10% when crystallized on PET-coated substrates compared to uncoated substrates. Overall, these results suggest that ACM can interact through hydrogen bonding with the PET-coated substrate, leading to faster nucleation. This investigation illustrates the effect of PET-coated substrates in the selective crystallization of ACM II in PEG as crystalline solid dispersions (CSDs). Ultimately, the results suggest the implementation of polymeric heteronucleants in melt crystallization processes, specifically, in advanced polymer-based formulation processes for the enhanced polymorphic form control of pharmaceutical compounds in CSDs.
Collapse
Affiliation(s)
- Giovanni López Burgos
- Department of Pharmaceutical Sciences, University of Puerto Rico, San Juan, Puerto Rico 00936, United States; Molecular Sciences Research Center, Crystallization Design Institute, University of Puerto Rico, San Juan, Puerto Rico 00926, United States
| | - José R Hernández-Espinell
- Molecular Sciences Research Center, Crystallization Design Institute, University of Puerto Rico, San Juan, Puerto Rico 00926, United States; Department of Chemistry, University of Puerto Rico, San Juan, Puerto Rico 00931, United States
| | - Tatiana Graciani-Massa
- Molecular Sciences Research Center, Crystallization Design Institute, University of Puerto Rico, San Juan, Puerto Rico 00926, United States; Department of Chemistry, University of Puerto Rico, San Juan, Puerto Rico 00931, United States
| | - Xin Yao
- Department of Chemistry, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Kennedy A Borchardt-Setter
- Department of Chemistry, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Lian Yu
- Department of Chemistry, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Vilmalí López-Mejías
- Molecular Sciences Research Center, Crystallization Design Institute, University of Puerto Rico, San Juan, Puerto Rico 00926, United States; Department of Chemistry, University of Puerto Rico, San Juan, Puerto Rico 00931, United States
| | - Torsten Stelzer
- Department of Pharmaceutical Sciences, University of Puerto Rico, San Juan, Puerto Rico 00936, United States; Molecular Sciences Research Center, Crystallization Design Institute, University of Puerto Rico, San Juan, Puerto Rico 00926, United States
| |
Collapse
|
37
|
Bassand C, Benabed L, Charlon S, Verin J, Freitag J, Siepmann F, Soulestin J, Siepmann J. 3D printed PLGA implants: APF DDM vs. FDM. J Control Release 2023; 353:864-874. [PMID: 36464064 DOI: 10.1016/j.jconrel.2022.11.052] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2022] [Revised: 11/21/2022] [Accepted: 11/29/2022] [Indexed: 12/23/2022]
Abstract
3D Printing offers a considerable potential for personalized medicines. This is especially true for customized biodegradable implants, matching the specific needs of each patient. Poly(lactic-co-glycolic acid) (PLGA) is frequently used as matrix former in biodegradable implants. However, yet relatively little is known on the technologies, which can be used for the 3D printing of PLGA implants. The aim of this study was to compare: (i) Arburg Plastic Freeforming Droplet Deposition Modeling (APF DDM), and (ii) Fused Deposition Modeling (FDM) to print mesh-shaped, ibuprofen-loaded PLGA implants. During APF DDM, individual drug-polymer droplets are deposited, fusing together to form filaments, which build up the implants. During FDM, continuous drug-polymer filaments are deposited to form the meshes. The implants were thoroughly characterized before and after exposure to phosphate buffer pH 7.4 using optical and scanning electron microscopy, GPC, DSC, drug release measurements and monitoring dynamic changes in the systems' dry & wet mass and pH of the bulk fluid. Interestingly, the mesh structures were significantly different, although the device design (composition & theoretical geometry) were the same. This could be explained by the fact that the deposition of individual droplets during APF DDM led to curved and rather thick filaments, resulting in a much lower mesh porosity. In contrast, FDM printing generated straight and thinner filaments: The open spaces between them were much larger and allowed convective mass transport during drug release. Consequently, most of the drug was already released after 4 d, when substantial PLGA set on. In the case of APF DDM printed implants, most of the drug was still entrapped at that time point and substantial polymer swelling transformed the meshes into more or less continuous PLGA gels. Hence, the diffusion pathways became much longer and ibuprofen release was controlled over 2 weeks.
Collapse
Affiliation(s)
- C Bassand
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - L Benabed
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - S Charlon
- IMT Lille Douai, École Nationale Supérieure Mines-Télécom Lille Douai, Materials & Processes Center, Cité Scientifique, Villeneuve d'Ascq Cedex, France
| | - J Verin
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Freitag
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - F Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Soulestin
- IMT Lille Douai, École Nationale Supérieure Mines-Télécom Lille Douai, Materials & Processes Center, Cité Scientifique, Villeneuve d'Ascq Cedex, France
| | - J Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France.
| |
Collapse
|
38
|
Extrusion-Based Technology in Additive Manufacturing: A Comprehensive Review. ARABIAN JOURNAL FOR SCIENCE AND ENGINEERING 2022. [DOI: 10.1007/s13369-022-07539-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
39
|
Martin‐Pastor M, Stoyanov E. Liquid crystalline phase behavior and hydration of hydroxypropyl cellulose in water: A liquid and solid
NMR
investigation. JOURNAL OF POLYMER SCIENCE 2022. [DOI: 10.1002/pol.20220536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Manuel Martin‐Pastor
- Unidad de Resonancia Magnética, Área de Infraestructuras de Investigación Universidad de Santiago de Compostela, Santiago de Compostela A Coruña Spain
| | | |
Collapse
|
40
|
Novel Approach to Pharmaceutical 3D-Printing Omitting the Need for Filament-Investigation of Materials, Process, and Product Characteristics. Pharmaceutics 2022; 14:pharmaceutics14112488. [PMID: 36432679 PMCID: PMC9695885 DOI: 10.3390/pharmaceutics14112488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 10/28/2022] [Accepted: 11/11/2022] [Indexed: 11/19/2022] Open
Abstract
The utilized 3D printhead employs an innovative hot-melt extrusion (HME) design approach being fed by drug-loaded polymer granules and making filament strands obsolete. Oscillatory rheology is a key tool for understanding the behavior of a polymer melt in extrusion processes. In this study, small amplitude shear oscillatory (SAOS) rheology was applied to investigate formulations of model antihypertensive drug Metoprolol Succinate (MSN) in two carrier polymers for pharmaceutical three-dimensional printing (3DP). For a standardized printing process, the feeding polymers viscosity results were correlated to their printability and a better understanding of the 3DP extrudability of a pharmaceutical formulation was developed. It was found that the printing temperature is of fundamental importance, although it is limited by process parameters and the decomposition of the active pharmaceutical ingredients (API). Material characterization including differential scanning calorimetry (DSC) and thermogravimetric analyses (TGA) of the formulations were performed to evaluate component miscibility and ensure thermal durability. To assure the development of a printing process eligible for approval, all print runs were investigated for uniformity of mass and uniformity of dosage in accordance with the European Pharmacopoeia (Ph. Eur.).
Collapse
|
41
|
Deon M, dos Santos J, de Andrade DF, Beck RCR. A critical review of traditional and advanced characterisation tools to drive formulators towards the rational development of 3D printed oral dosage forms. Int J Pharm 2022; 628:122293. [DOI: 10.1016/j.ijpharm.2022.122293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2022] [Revised: 10/03/2022] [Accepted: 10/09/2022] [Indexed: 10/31/2022]
|
42
|
Recent Advances in Amorphous Solid Dispersions: Preformulation, Formulation Strategies, Technological Advancements and Characterization. Pharmaceutics 2022; 14:pharmaceutics14102203. [PMID: 36297638 PMCID: PMC9609913 DOI: 10.3390/pharmaceutics14102203] [Citation(s) in RCA: 27] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 09/27/2022] [Accepted: 10/13/2022] [Indexed: 11/05/2022] Open
Abstract
Amorphous solid dispersions (ASDs) are among the most popular and widely studied solubility enhancement techniques. Since their inception in the early 1960s, the formulation development of ASDs has undergone tremendous progress. For instance, the method of preparing ASDs evolved from solvent-based approaches to solvent-free methods such as hot melt extrusion and Kinetisol®. The formulation approaches have advanced from employing a single polymeric carrier to multiple carriers with plasticizers to improve the stability and performance of ASDs. Major excipient manufacturers recognized the potential of ASDs and began introducing specialty excipients ideal for formulating ASDs. In addition to traditional techniques such as differential scanning calorimeter (DSC) and X-ray crystallography, recent innovations such as nano-tomography, transmission electron microscopy (TEM), atomic force microscopy (AFM), and X-ray microscopy support a better understanding of the microstructure of ASDs. The purpose of this review is to highlight the recent advancements in the field of ASDs with respect to formulation approaches, methods of preparation, and advanced characterization techniques.
Collapse
|
43
|
Recent advancements in additive manufacturing techniques employed in the pharmaceutical industry: A bird's eye view. ANNALS OF 3D PRINTED MEDICINE 2022. [DOI: 10.1016/j.stlm.2022.100081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
44
|
Parulski C, Gresse E, Jennotte O, Felten A, Ziemons E, Lechanteur A, Evrard B. Fused deposition modeling 3D printing of solid oral dosage forms containing amorphous solid dispersions: How to elucidate drug dissolution mechanisms through surface spectral analysis techniques? Int J Pharm 2022; 626:122157. [PMID: 36055443 DOI: 10.1016/j.ijpharm.2022.122157] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 08/26/2022] [Accepted: 08/27/2022] [Indexed: 11/27/2022]
Abstract
Many active principles belong to the second class of the Biopharmaceutics Classification System due to their low aqueous solubility. Elaboration of new solid oral forms by hot-melt extrusion and fused deposition modeling appears as a promising tool to increase the dissolution rate of these drugs. Indeed, hot-melt extrusion allows the amorphisation of drugs and forms with complex geometries are built by 3D printing. Therefore, the goal of this work is to enhance the dissolution rate of poorly soluble drugs using hot-melt extrusion coupled with fused deposition modeling. Four formulations containing Affinisol® 15LV, Kollidon® VA64 and a challenging amount of itraconazole (25% (wt.)) were successfully printed into forms of 20, 50 and 80% infill densities. Differential scanning calorimetry analysis has shown that itraconazole remained amorphous during 52 weeks. The drug release rate was highly improved compared to itraconazole in a crystalline form. The dissolution rate was influenced by the infill density and the polymer composition of printed forms which could modify respectively the surface to volume ratio and the distribution of the components in the printed forms. One formulation printed with 20% infill density even had a solubility profile similar to that of Sporanox®, the commercialized drug product in Belgium.
Collapse
Affiliation(s)
- Chloé Parulski
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium.
| | - Eva Gresse
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium
| | - Olivier Jennotte
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium
| | - Alexandre Felten
- Synthesis, Irradiation and Analysis of Materials (SIAM) platform, University of Namur, Rue de Bruxelles 61, 5000 Namur, Belgium
| | - Eric Ziemons
- Laboratory of Pharmaceutical Analytical Chemistry, Center for Interdisciplinary Research on Medicines (CIRM), ViBra-Sante Hub, Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium
| | - Anna Lechanteur
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium
| | - Brigitte Evrard
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium
| |
Collapse
|
45
|
Ghanizadeh Tabriz A, Nandi U, Scoutaris N, Sanfo K, Alexander B, Gong Y, Hui HW, Kumar S, Douroumis D. Personalised Paediatric Chewable Ibuprofen Tablets Fabricated Using 3D Micro-extrusion Printing Technology. Int J Pharm 2022; 626:122135. [PMID: 36028083 DOI: 10.1016/j.ijpharm.2022.122135] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 08/03/2022] [Accepted: 08/18/2022] [Indexed: 10/15/2022]
Abstract
Three-dimensional (3D) printing is becoming an attractive technology for the design and development of personalized paediatric dosage forms with improved palatability. In this work micro-extrusion based printing was implemented for the fabrication of chewable paediatric ibuprofen (IBU) tablets by assessing a range of front runner polymers in taste masking. Due to the drug-polymer miscibility and the IBU plasticization effect, micro-extrusion was proved to be an ideal technology for processing the drug/polymer powder blends for the printing of paediatric dosage forms. The printed tablets presented high printing quality with reproducible layer thickness and a smooth surface. Due to the drug-polymer interactions induced during printing processing, IBU was found to form a glass solution confirmed by differential calorimetry (DSC) while H-bonding interactions were identified by confocal Raman mapping. IBU was also found to be uniformly distributed within the polymer matrices at molecular level. The tablet palatability was assessed by panellists and revealed excellent taste masking of the IBU's bitter taste. Overall micro-extrusion demonstrated promising processing capabilities of powder blends for rapid printing and development of personalised dosage forms.
Collapse
Affiliation(s)
- Atabak Ghanizadeh Tabriz
- Faculty of Engineering and Science, School of Science, University of Greenwich, Chatham Maritime, Chatham, Kent ME4 4TB, UK; CIPER Centre for Innovation and Process Engineering Research, Kent, ME4 4TB, UK
| | - Uttom Nandi
- Faculty of Engineering and Science, School of Science, University of Greenwich, Chatham Maritime, Chatham, Kent ME4 4TB, UK; CIPER Centre for Innovation and Process Engineering Research, Kent, ME4 4TB, UK
| | - Nicolaos Scoutaris
- Faculty of Engineering and Science, School of Science, University of Greenwich, Chatham Maritime, Chatham, Kent ME4 4TB, UK; CIPER Centre for Innovation and Process Engineering Research, Kent, ME4 4TB, UK
| | - Karifa Sanfo
- Faculty of Engineering and Science, School of Science, University of Greenwich, Chatham Maritime, Chatham, Kent ME4 4TB, UK
| | - Bruce Alexander
- Faculty of Engineering and Science, School of Science, University of Greenwich, Chatham Maritime, Chatham, Kent ME4 4TB, UK
| | - Yuchuan Gong
- Drug Product Development, Bristol Myers Squibb (formerly Celgene Corporation), 556 Morris Avenue, Summit, NJ 07901, USA.
| | - Ho-Wah Hui
- Drug Product Development, Bristol Myers Squibb (formerly Celgene Corporation), 556 Morris Avenue, Summit, NJ 07901, USA
| | - Sumit Kumar
- Drug Product Development, Bristol Myers Squibb (formerly Celgene Corporation), 556 Morris Avenue, Summit, NJ 07901, USA.
| | - Dennis Douroumis
- Faculty of Engineering and Science, School of Science, University of Greenwich, Chatham Maritime, Chatham, Kent ME4 4TB, UK; CIPER Centre for Innovation and Process Engineering Research, Kent, ME4 4TB, UK.
| |
Collapse
|
46
|
Moroni S, Khorshid S, Aluigi A, Tiboni M, Casettari L. Poly(3-hydroxybutyrate): a potential biodegradable excipient for direct 3D printing of pharmaceuticals. Int J Pharm 2022; 623:121960. [PMID: 35753539 DOI: 10.1016/j.ijpharm.2022.121960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 06/17/2022] [Accepted: 06/20/2022] [Indexed: 10/17/2022]
Abstract
During the past decades, 3D printing has revolutionised different areas of research. Despite the considerable progress achieved in 3D printing of pharmaceuticals, the limited choice of suitable materials remains a challenge to overcome. The growing search for sustainable excipients has led to an increasing interest in biopolymers. Poly(3-hydroxybutyrate) (PHB) is a biocompatible and biodegradable biopolymer obtained from bacteria that could be efficiently employed in the pharmaceutical field. Here we aimed to demonstrate its potential application as a thermoplastic material for personalised medicine through 3D printing. More specifically, we processed PHB by using direct powder extrusion, a one-step additive manufacturing technique. To assess and denote the feasibility and versatility of the process, a 3D square model was manufactured in different dimensions (side x height: 12x2 mm; 18x2 mm; 24x2 mm) and loaded with increasing percentages of a model drug (up to 30% w/w). The manufacturing process was influenced by the drug content, and indeed, an increase in the amount of the drug determined a reduction in the printing temperature, without affecting the other parameters (such as the layer height). The composition of the model squares was investigated using Fourier-transform infrared spectroscopy, the resulting spectra confirmed that the starting materials were successfully incorporated into the final formulations. The thermal behaviour of the printed systems was characterized by differential scanning calorimetry, and thermal gravimetric analysis. Moreover, the sustained drug release profile of the formulations was performed over 21 days and showed to be dependent on the dimensions of the printed object and on the amount of loaded drug. Indeed, the formulation with 30% w/w in the dimension 24x2 mm released the highest amount of drug. Hence, the results suggested that PHB and direct powder extrusion technique could be promising tools for the manufacturing of prolonged release and personalised drug delivery forms.
Collapse
Affiliation(s)
- Sofia Moroni
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento, 6, 61029 Urbino (PU), Italy
| | - Shiva Khorshid
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento, 6, 61029 Urbino (PU), Italy
| | - Annalisa Aluigi
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento, 6, 61029 Urbino (PU), Italy
| | - Mattia Tiboni
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento, 6, 61029 Urbino (PU), Italy
| | - Luca Casettari
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento, 6, 61029 Urbino (PU), Italy
| |
Collapse
|
47
|
Bácskay I, Ujhelyi Z, Fehér P, Arany P. The Evolution of the 3D-Printed Drug Delivery Systems: A Review. Pharmaceutics 2022; 14:pharmaceutics14071312. [PMID: 35890208 PMCID: PMC9318419 DOI: 10.3390/pharmaceutics14071312] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 06/15/2022] [Accepted: 06/18/2022] [Indexed: 11/16/2022] Open
Abstract
Since the appearance of the 3D printing in the 1980s it has revolutionized many research fields including the pharmaceutical industry. The main goal is to manufacture complex, personalized products in a low-cost manufacturing process on-demand. In the last few decades, 3D printing has attracted the attention of numerous research groups for the manufacturing of different drug delivery systems. Since the 2015 approval of the first 3D-printed drug product, the number of publications has multiplied. In our review, we focused on summarizing the evolution of the produced drug delivery systems in the last 20 years and especially in the last 5 years. The drug delivery systems are sub-grouped into tablets, capsules, orodispersible films, implants, transdermal delivery systems, microneedles, vaginal drug delivery systems, and micro- and nanoscale dosage forms. Our classification may provide guidance for researchers to more easily examine the publications and to find further research directions.
Collapse
Affiliation(s)
- Ildikó Bácskay
- Healthcare Industry Institute, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary
| | - Zoltán Ujhelyi
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary
| | - Pálma Fehér
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary
| | - Petra Arany
- Healthcare Industry Institute, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary
| |
Collapse
|
48
|
Wang Q, Chan HN, Wu H. Replicating 3D printed structures into functional materials. J Appl Polym Sci 2022. [DOI: 10.1002/app.52655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Qiaoyi Wang
- Department of Chemistry The Hong Kong University of Science and Technology Kowloon Hong Kong
| | - Ho Nam Chan
- Department of Chemistry The Hong Kong University of Science and Technology Kowloon Hong Kong
| | - Hongkai Wu
- Department of Chemistry The Hong Kong University of Science and Technology Kowloon Hong Kong
| |
Collapse
|
49
|
Muhindo D, Ashour EA, Almutairi M, Repka MA. Development and evaluation of raloxifene hydrochloride-loaded subdermal implants using hot-melt extrusion technology. Int J Pharm 2022; 622:121834. [PMID: 35597391 DOI: 10.1016/j.ijpharm.2022.121834] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Revised: 05/10/2022] [Accepted: 05/13/2022] [Indexed: 01/15/2023]
Abstract
Implantable drug delivery systems are known to provide great patient compliance and allow for controlled delivery of drugs over a prolonged period of time. This study aimed to prepare novel polycaprolactone/polyethylene glycol-based raloxifene hydrochloride subdermal solid cylindrical implants using a single-step hot-melt extrusion (HME) continuous process, for the provision of a sustained and prolonged release of RX-HCl as a cornerstone and alternative treatment and prevention option of osteoporosis, most especially post-menopausal osteoporosis, and invasive breast cancer, while providing better clinical outcomes by circumventing clinical and biopharmaceutical hurdles like first-pass metabolism and patient non-adherence and incompliance associated with the oral dosage forms of raloxifene hydrochloride. The 11-mm co-rotating twin-screw extruder was used to prepare the implants. The prepared cylindrical-shaped solid implants with dimensions of 10 mm (length) by 2 mm (diameter) were characterized by DSC, PXRD, FTIR, SEM, and in vitro dissolution analysis. Based on the physicochemical characterization of the prepared implants, the HME fabrication technology and optimized process parameters were determined to be acceptable and suitable. The prepared implants showed no obvious burst release and no significant amounts of drug on the surface of the implants. F-1, F-2, and F-3 implant batches showed a maximum cumulative percent drug release of 82.9 %, 42.2 %, and 20.6 %, respectively, in a period of 30 days, and 100 % drug release would be expected in a period of about 40 days (F-1), 72 days (F-2), and up to 150 days (F-3) by simple extrapolation. Interestingly, implant batches with a low drug load exhibited a relatively faster and higher rate of release of the drug compared to implant batches with high drug loading. In the present study, a single-step HME process was successfully used to fabricate RX-HCl-loaded subdermal implants, that could potentially be used as a cornerstone regimen in the treatment and prevention of osteoporosis, most especially post-menopausal osteoporosis, by providing release of RX-HCl over a long time period, and avoiding the clinical inconveniences and possible patient incompliance caused by daily administration of the drug.
Collapse
Affiliation(s)
- Derick Muhindo
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, United States
| | - Eman A Ashour
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, United States
| | - Mashan Almutairi
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, United States; Department of Pharmaceutics, College of Pharmacy, University of Hail, Hail 81442, Saudi Arabia
| | - Michael A Repka
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, United States; Pii Center for Pharmaceutical Technology, School of Pharmacy, University of Mississippi, University, MS 38677, United States.
| |
Collapse
|
50
|
Cao X, Xuan S, Gao Y, Lou C, Deng H, Gong X. 3D Printing Ultraflexible Magnetic Actuators via Screw Extrusion Method. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2022; 9:e2200898. [PMID: 35347888 PMCID: PMC9165489 DOI: 10.1002/advs.202200898] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Revised: 03/17/2022] [Indexed: 05/06/2023]
Abstract
Soft magnetic actuators with programmable structure design and controllable deformation ability based on 3D printing technology have attracted extensive attention. In this paper, a novel 3D printing strategy is developed to manufacture the ultraflexible magnetic actuator, in which the printed material is composed of magnetic particles and thermoplastic rubber materials. Different from the traditional fused deposition printing, this printing strategy introduces screw extrusion technology to the heating components of the printer to overcome the problem of filament buckling in the flexible material. Thus, the tensile modulus of the printed products can be reduced to as low as ≈2 MPa. Based on the above method, biomimetic magnetic actuators of the sucker and the pump are constructed for adhering and releasing object and pumping liquid. The contraction performance of the magnetic actuator is studied via a series of experiments and the magnetic field-induced deformation is analyzed by the multiphysics-based finite element model. This work proves that ultraflexible magnetic actuators fabricated by this 3D printing strategy show broad prospects in the fields of soft robotics and bionics.
Collapse
Affiliation(s)
- Xufeng Cao
- CAS Key Laboratory of Mechanical Behavior and Design of MaterialsDepartment of Modern MechanicsUniversity of Science and Technology of ChinaHefei230027China
| | - Shouhu Xuan
- CAS Key Laboratory of Mechanical Behavior and Design of MaterialsDepartment of Modern MechanicsUniversity of Science and Technology of ChinaHefei230027China
| | - Yinduan Gao
- CAS Key Laboratory of Mechanical Behavior and Design of MaterialsDepartment of Modern MechanicsUniversity of Science and Technology of ChinaHefei230027China
| | - Congcong Lou
- CAS Key Laboratory of Mechanical Behavior and Design of MaterialsDepartment of Modern MechanicsUniversity of Science and Technology of ChinaHefei230027China
| | - Huaxia Deng
- CAS Key Laboratory of Mechanical Behavior and Design of MaterialsDepartment of Modern MechanicsUniversity of Science and Technology of ChinaHefei230027China
| | - Xinglong Gong
- CAS Key Laboratory of Mechanical Behavior and Design of MaterialsDepartment of Modern MechanicsUniversity of Science and Technology of ChinaHefei230027China
| |
Collapse
|